Related by context. All words. (Click for frequent words.) 72 APOPTONE 70 Symadex 69 Triolex 68 Traficet EN 68 PXD# 68 #ME# 68 INCB# [001] 68 Plicera 68 OXi# 68 ENMD # 67 teriflunomide 67 vidofludimus 67 LY# [003] 67 Serdaxin 67 CCX# 67 otelixizumab 67 DXL# 67 JAK inhibitors 67 R#/MEM # 67 ganetespib 66 urocortin 2 66 preclinically 66 Apoptone 66 Panzem 66 favorable pharmacokinetic profile 66 HuMax CD# 66 XmAb# 66 PSN# [002] 66 PD LID 66 CORT # 66 decitabine 66 Xanafide 66 Panzem R 66 nonclinical studies 66 milatuzumab 66 TACI Ig 65 EndoTAG TM -1 65 pomalidomide 65 Interferon alpha 65 riociguat 65 ISIS # 65 PS# [001] 65 JAK1 65 atacicept 65 VEGF inhibitors 65 orally administered inhibitor 65 receptor inhibitor 65 Sym# 65 PRT# 65 mTOR inhibitors 65 NGX# 65 sodium glucose cotransporter 65 LY# [002] 65 radezolid 65 elotuzumab 65 oral prodrug 65 tanespimycin 65 tezampanel 65 Posiphen 65 CGEN # 65 Bezielle 65 orally bioavailable 65 Vidofludimus 64 tocilizumab 64 insulin sensitizers 64 cannabinor 64 PEG PAL 64 lupus nephritis 64 INCB# [002] 64 Amigal 64 Dasatinib 64 selective modulator 64 eniluracil 64 AEG# 64 MAGE A3 ASCI 64 BAY #-# 64 MDV# 64 liposomal formulation 64 samalizumab 64 TELCYTA 64 axitinib 64 Archexin 64 MGCD# [001] 64 PEG SN# 64 IRX 2 64 valopicitabine 64 HuMax CD4 64 Azixa 64 rFIXFc 64 cMET 64 HGS ETR1 64 HuLuc# 64 HGS ETR2 64 Bortezomib 64 Phase Ib study 64 Phenoptin 64 eltrombopag 64 brivaracetam 64 nanoviricides 64 HspE7 63 Telintra 63 Genz # 63 CBLC# 63 KNS # 63 SRT# [003] 63 delafloxacin 63 ataluren 63 IL 1ß 63 SGS# 63 TKM ApoB 63 MEK inhibitors 63 antiangiogenic 63 MEK inhibitor 63 Cethrin 63 pharmacodynamic effects 63 proteasome inhibitor 63 angiogenesis inhibitor 63 ProSavin 63 iroxanadine 63 Pimavanserin 63 HQK 63 JAK3 63 Alzhemed TM 63 diabetic neuropathic pain 63 Azedra 63 CIMZIA TM 63 lomitapide 63 S/GSK# 63 EOquin 63 vascular disrupting agent 63 preclinical studies 63 cediranib 63 Ceflatonin 63 #D#C# 63 ATL# [001] 63 MYDICAR ® 63 HCV protease 63 GAMMAGARD 63 tafamidis 63 Guanilib 63 JAK inhibitor 63 seliciclib 63 INT# [002] 63 Gleevec resistant 63 anti amnesic 63 HuMax EGFr 63 Phase 2a trial 63 Tasimelteon 63 EGS# 63 Tyrima 63 IL 1beta 63 obatoclax 63 Actilon 63 Seliciclib 63 Mipomersen 63 RhuDex R 62 PCK# 62 Zerenex 62 Onconase 62 CDK inhibitor 62 oral bioavailability 62 beta 1a 62 Ocrelizumab 62 GALNS 62 GRN#L 62 BAL# [002] 62 Technosphere Insulin 62 YONDELIS 62 mapatumumab 62 forodesine 62 entinostat 62 ALB # 62 LT NS# 62 interferon beta 62 rhIGFBP 3 62 HE# [002] 62 Bicifadine 62 leukemia AML 62 bafetinib 62 AZILECT R 62 ISTODAX 62 posaconazole 62 pramlintide 62 Virulizin ® 62 glucagon receptor 62 systemically administered 62 GRN# 62 TMC# [002] 62 PRTX 62 receptor tyrosine kinase inhibitor 62 antiviral activity 62 LAF# 62 Phase IIb trials 62 fibrotic disease 62 PROMACTA 62 mGluR2 NAM 62 trodusquemine 62 tumor xenograft models 62 PLX cells 62 IDX# 62 alagebrium 62 ALN TTR 62 ICA # 62 EGFr 62 Hsp# inhibition 62 Huntexil 62 metreleptin 62 nalbuphine ER 62 OncoVEX GM CSF 62 MEK inhibitor RDEA# 62 dirucotide 62 HDAC inhibitors 62 huC# DM4 62 GDIR 62 ALK inhibitor 62 rHuPH# 62 darinaparsin 62 Nuvion 62 Factor VIIa 62 visilizumab 62 maximally tolerated dose 62 CA4P 62 zanolimumab 62 Omacetaxine mepesuccinate 62 antiangiogenic activity 62 enzastaurin 62 ocrelizumab 62 Ostarine 62 HCD# [002] 62 pradefovir 62 preclinical efficacy 62 Carfilzomib 62 RhuDex 62 CCR2 62 Cytolin ® 62 viral kinetics 62 ASONEP 62 Cethromycin 62 anti leukemic 62 Rasagiline 62 dose cohorts 62 Chemophase 62 Thiovir 62 cilengitide 62 pharmacokinetic characteristics 62 AVN# [001] 62 dacetuzumab 62 PROCHYMAL 62 ORMD 62 DCCR 62 TBC# 62 IFN alpha 62 GSK# [001] 62 pharmacodynamic 62 pertuzumab 62 darapladib 62 pan HDAC inhibitor 62 pharmacological chaperone 62 PRX # 62 CYC# 62 Vernakalant 62 Reverset 61 Saxagliptin 61 R roscovitine 61 rindopepimut 61 Targretin 61 talactoferrin 61 FluCide 61 velafermin 61 preclinical pharmacokinetic 61 LymphoStat B 61 RGB # 61 Anavex #-# 61 nitazoxanide 61 imatinib Gleevec ® 61 CTAP# Capsules 61 Prestara 61 Viramidine 61 Valortim ® 61 generation purine nucleoside 61 secretory phospholipase A2 sPLA2 61 GLYX 61 GFT# 61 IFN α 61 ELACYT 61 HGS# 61 GSK# [002] 61 octreotide acetate 61 elacytarabine 61 selective androgen receptor modulator 61 uricase 61 AZD# 61 torezolid phosphate 61 registrational trial 61 PTC# 61 Talabostat 61 methylnaltrexone 61 Sudhir Agrawal D.Phil 61 novel VDA molecule 61 ZYBRESTAT 61 pharmacokinetic PK profile 61 TELINTRA 61 RAV# 61 Valortim 61 bevirimat 61 dexpramipexole 61 somatostatin analogue 61 TREANDA 61 glufosfamide 61 triphendiol 61 rNAPc2 61 omecamtiv mecarbil 61 Aurexis 61 Aclidinium 61 miR #a [001] 61 IFN beta 61 mertansine 61 Asentar 61 Laquinimod 61 PDE4 inhibitor 61 azacitidine 61 renal toxicity 61 blinatumomab 61 thrombopoietin 61 OHR/AVR# 61 SAR# [004] 61 ON #.Na 61 Phase IIB 61 baminercept 61 lumiliximab 61 Androxal TM 61 ELND# 61 Preclinical studies suggest 61 PTHrP 61 Tavocept 61 Synavive 61 TRO# 61 somatostatin analog 61 metaglidasen 61 canakinumab 61 leukemia CLL 61 GRNCM1 61 Imprime PGG 61 octreotide 61 mg kg dose 61 veltuzumab 61 RhuDex ® 61 K ras mutations 61 ImmunoVEX HSV2 61 pharmacodynamic profile 61 Epanova 61 epigenetic therapies 61 ThGRF 61 Zybrestat 61 histone deacetylase inhibitor 61 RDEA# 61 insulin sensitizing 61 dose proportionality 61 oral FTY# 61 A3 adenosine receptor 61 GLP toxicology studies 61 Glufosfamide 61 anti fibrotic 61 nucleoside analogs 61 Ophena TM 61 huN# DM1 61 Phase #/#a trial 61 masitinib 61 preclinical 61 depsipeptide 61 targeting CD# 61 FLT3 61 pharmacodynamic properties 61 phase IIa clinical 61 CYT# potent vascular disrupting 61 PROSTVAC VF 61 Capesaris 61 corticosteroid dexamethasone 61 hGH CTP 61 orally dosed 61 Amrubicin 61 Atiprimod 61 nanoviricide 61 Virulizin R 61 rilonacept 61 NN# [001] 61 pegylated 61 PSMA ADC 61 exon skipping 61 SERMs 61 fosbretabulin 61 ADAGIO study 61 nucleotide analog 61 anti CD3 antibody 61 interferon IFN 61 CD# antibody [001] 61 zileuton 61 IL #E 61 mTOR inhibitor 61 tyrosine kinase inhibitor 60 insulin sensitizer 60 PBT2 60 Safinamide 60 Phase #b/#a trial 60 tramiprosate Alzhemed TM 60 peptide antigens 60 AEGR 60 volociximab 60 ruxolitinib 60 Tarvacin 60 CoFactor 60 Dapagliflozin 60 CR# vcMMAE 60 Teriflunomide 60 IMA# 60 anticancer agent 60 Menerba 60 Aptivus ® 60 Solorel TM 60 Homspera 60 evaluating tivozanib 60 Nasulin 60 alvespimycin 60 phase IIb clinical 60 Phase IIb clinical trials 60 Marqibo 60 induce apoptosis 60 PEGPH# 60 MB# [004] 60 tolerability profiles 60 somatostatin 60 immunomodulatory 60 SILENOR TM 60 anti CD3 60 bardoxolone 60 PNP inhibitor 60 DFMO 60 CCR9 antagonist 60 virus HCV protease inhibitor 60 VAPRISOL 60 laquinimod 60 AP# [003] 60 vitro experiments 60 radiation sensitizer 60 belinostat 60 nanoviricide drug 60 serotonin receptor 60 bortezomib Velcade 60 antiproliferative effects 60 docetaxel Taxotere ® 60 tolerability profile 60 ramelteon 60 antitumour activity 60 AMD# [003] 60 lintuzumab 60 #beta HSD1 60 Hsp# inhibitors 60 IMGN# 60 Arikace 60 MultiStem 60 Allovectin 7 ® 60 XL# inhibits 60 PTP 1B 60 EOquin TM 60 iSONEP 60 apremilast 60 MAXY G# 60 C1 INH 60 Thiarabine 60 APD# 60 ZFP Therapeutic 60 pharmacokinetic properties 60 caspofungin 60 HCV protease inhibitors 60 BiovaxID 60 Zoraxel 60 antitumor efficacy 60 Azedra TM 60 eprotirome 60 ANAVEX #-# [003] 60 Voreloxin 60 FTY# 60 AQ4N 60 2 methoxyestradiol 60 BNC# 60 interferon alfa 60 polymerase inhibitor 60 pharmacokinetic profile 60 inhibitor RG# 60 tramiprosate 60 statistically significant efficacy 60 MET amplification 60 liprotamase 60 Spheramine 60 CRLX# 60 AAG geldanamycin analog 60 ganaxolone 60 Arimoclomol 60 Golimumab 60 tgAAC# 60 canagliflozin 60 TRV# [001] 60 neutralizing antibody 60 5 HT2C receptor 60 CIMZIA ™ 60 S1P 60 idarubicin 60 oritavancin 60 HCV replicon 60 JAK2 inhibitors 60 bexarotene 60 CINTREDEKIN BESUDOTOX 60 inhibit metastasis 60 midstage clinical 60 Diamyd ® 60 aurora kinase 60 Vilazodone 60 antiviral efficacy 60 Linaclotide 60 Omacetaxine 60 Kevetrin 60 E1 INT TM 60 Annamycin 60 BiTE antibodies 60 nucleoside analog 60 neuroprotective properties 60 epothilone 60 investigational monoclonal antibody 60 ANAVEX #-# [001] 60 anticancer compound 60 IMC A# 60 INCB# [003] 60 Chrysalin 60 myeloproliferative disorders 60 HER3 60 relapsed SCLC 60 Granulocyte Colony Stimulating Factor 60 PKC# 60 DB# [003] 60 PEGylated interferon beta 1a 60 TriRima 60 retapamulin 60 CEQ# 60 custirsen 60 Altastaph 60 interleukin IL -# 60 elvucitabine 60 Panzem R NCD 60 VEGF inhibitor 60 safinamide 60 SNT MC# 60 ARIKACE 60 mecamylamine 60 myelofibrosis 60 serotonin synthesis 60 KRN# 60 DDP# 60 protein tyrosine phosphatase 1B 60 HSP# inhibitor 60 ponatinib 60 DAVANAT 60 muscarinic 60 imatinib therapy 60 Gleevec imatinib mesylate 60 bleomycin 60 proteasome inhibitors 60 ARIKACE ™ 60 CCR9 60 GRNVAC1 60 panitumumab Vectibix 60 vivo efficacy 60 #HT#A 60 PEGylated 60 antitumor activity 60 gastrin 60 TOLAMBA 59 BRAF inhibitor 59 SIRT1 activators 59 investigational humanized monoclonal antibody 59 TLK# 59 humanized anti 59 relapsing remitting multiple sclerosis 59 talabostat 59 regorafenib 59 partial agonist 59 reslizumab 59 anakinra 59 iclaprim 59 Fx #A 59 ALGRX 59 GKAs 59 Blinatumomab 59 calcitonin 59 Alocrest 59 docetaxel Taxotere R 59 IND submission 59 MNTX 59 Zavesca R 59 molecularly targeted 59 vandetanib 59 insulin degludec 59 SYN# 59 CYT# 59 muraglitazar 59 olmesartan 59 Aplidin 59 small molecule defensin 59 SPC# [001] 59 L BLP# 59 sitaxsentan 59 SomatoKine 59 myeloproliferative diseases 59 vorinostat 59 alvimopan 59 Aurora kinase 59 fulvestrant 59 NLX P# 59 ofatumumab 59 endostatin 59 Fc fusion protein 59 ACZ# 59 aplindore 59 pharmacokinetic interactions 59 humanized antibodies 59 5alpha reductase 59 Phase IIa trial 59 Neurodex 59 amrubicin 59 XL# anticancer compounds 59 PI3K inhibitor 59 prucalopride 59 oral JAK1 59 EMBEDA ™ 59 bosutinib 59 pralatrexate 59 PROSTVAC TM 59 CD# monoclonal antibody 59 sargramostim 59 Pradefovir 59 Iloperidone 59 ANAVEX #-# [002] 59 pharmacodynamic markers 59 clusterin 59 Preclinical studies 59 docetaxel chemotherapy 59 CINQUIL 59 hematological cancers 59 tipifarnib 59 ATL/TV# 59 Ofatumumab 59 T#I [002] 59 highly immunogenic 59 receptor blocker 59 lanreotide 59 Miraxion 59 androgen receptor AR 59 sapacitabine 59 Corlux 59 dyskinesia PD LID 59 antisense drug 59 eculizumab 59 refractory AML 59 tecarfarin 59 deacetylase inhibitors 59 tyrosine phosphorylation 59 Amplimexon 59 EFAPROXYN 59 LymphoStat B belimumab 59 Janus kinase 59 tesetaxel 59 EpCAM 59 potent inhibition 59 CYP #A# 59 pexiganan 59 dimebon 59 PI3K/Akt pathway inhibitor 59 synthetic retinoid 59 immune modulation 59 IAP inhibitor 59 mTOR inhibition 59 Tezampanel 59 Aflibercept 59 GHRH 59 generation NNRTI 59 lesinurad 59 MUC1 59 erlotinib Tarceva ® 59 generation antisense inhibitor 59 olaparib 59 TNFa 59 CTLA 4 59 phase IIb study 59 ALN TTR# 59 pro angiogenic 59 tolvaptan 59 NV1FGF 59 UPLYSO 59 PEG Interferon lambda 59 romidepsin 59 antiapoptotic 59 CG# [003] 59 RSD# 59 JAK2 59 Arranon 59 budesonide foam 59 Locteron 59 neuroregenerative 59 tyrosine kinase inhibitors 59 vildagliptin 59 rFVIIIFc 59 interferon therapy 59 tezampanel NGX# 59 SinuNase 59 cardiac toxicity 59 Torisel 59 GGF2 59 Tarceva TM 59 immune modulatory 59 Darinaparsin 59 JAK2 inhibitor 59 CCR5 mAb 59 potent antiviral 59 leukemia ALL 59 protein kinase inhibitor 59 TG# [003] 59 refractory gout 59 IFN γ 59 TH# [003] 59 tubulin inhibitor 59 phase 2a 59 Valortim R 59 SGLT2 59 teplizumab 59 SARMs 59 APTIVUS r 59 MBP# [001] 59 Phase 2a 59 brostallicin 59 MAb 59 rhThrombin 59 NP2 Enkephalin 59 SB# ONX 59 GED aPC 59 AGHD 59 oral rivaroxaban 59 preclinical models 59 immune stimulatory 59 uric acid lowering 59 VA# [002] 59 class mGluR5 inhibitor 59 Protelos 59 gemcitabine Gemzar ® 59 metastatic RCC 59 XL# [003] 59 E#F# 59 Pruvel 59 peripherally acting 59 dose proportional pharmacokinetics 59 ENaC 59 Perifosine 59 dose cohort 59 multicenter Phase II 59 VEGF receptor 59 vascular disrupting agents 59 EDEMA3 59 octreotide implant 59 clinically meaningful 59 phase Ib 59 NS5A 59 imatinib Gleevec 59 dosing cohort 59 ZOLINZA 59 Relivar 59 neurotrophic factor 59 MabCampath 59 GAP #B# 59 T#I mutant 59 EGFRvIII 59 ospemifene 59 siRNA mediated 59 biologic therapy 59 CIPN 59 sphingosine kinase 59 myelofibrosis polycythemia vera 59 pafuramidine 59 pegylated interferons 59 fluvastatin 59 Anidulafungin 59 Dalbavancin 59 thymalfasin 59 DHFR 59 APTIVUS 59 demonstrated antitumor activity 59 sunitinib Sutent ® 59 VIDAZA 59 siRNA therapeutics 59 EGFR TKI 59 BCX# 59 pharmacodynamic PD 59 antidepressant efficacy 59 VEGFb 59 Cetrorelix 59 Lisofylline 59 HIF PHI 59 PGE2 59 Bendavia 59 Vitaxin 59 NEUMUNE 59 Prodarsan ® 59 PANVAC VF 59 anti proliferative 59 TB4 59 Epothilones 59 efficacy endpoint 59 varespladib 59 vivo validation 59 Desmoteplase 59 neurotrophic 59 BCR ABL inhibitor 59 pharmacokinetic PK study 59 HCV protease inhibitor 59 forodesine hydrochloride 59 insulin analogs 59 Th2 cytokines 58 p# activation 58 LSI #P 58 INVEGA ® 58 lucinactant 58 splice variants 58 Campath alemtuzumab 58 iloperidone 58 activin 58 glucocorticoid receptor 58 AzaSite Plus 58 T2DM 58 oral picoplatin 58 calcineurin inhibitors 58 mGluR5 NAM 58 receptor antagonists 58 immune modulator 58 AZILECT ® 58 PYY 58 vitro cytotoxicity 58 Zolinza 58 pharmacokinetic studies 58 GIST tumors 58 cyclin dependent kinase inhibitor 58 pramlintide metreleptin combination 58 mCRC patients 58 interferon alpha 58 heavily pretreated patients 58 chemopreventive agent 58 Elagolix 58 phase IIb 58 ALN VSP 58 personalized immunotherapy 58 xanthine oxidase inhibitor 58 Proxinium TM 58 TLR9 58 Vascugel 58 PMX # 58 adecatumumab 58 Curaxin CBLC# 58 castration resistant prostate cancer 58 cetuximab Erbitux R 58 alefacept 58 cardioprotective effects 58 thalidomide Thalomid 58 myeloproliferative 58 IL# PE#QQR 58 bicifadine 58 rBChE 58 OvaRex ® MAb 58 Beta catenin pathway 58 IMiDs 58 Lixivaptan 58 Lisofylline LSF 58 fumagillin nanoparticles 58 refractory CLL 58 Phase 1b 58 teduglutide 58 Akt activation 58 Epratuzumab 58 ADX# 58 AVE# 58 Vandetanib 58 HIF 1alpha 58 vilazodone 58 Androxal 58 alemtuzumab Campath 58 ara C 58 vivo potency 58 potent inhibitors 58 goserelin 58 antithrombotic 58 eliglustat tartrate 58 PEGylated anti 58 PlGF 58 Aliskiren 58 Phenserine 58 Afatinib 58 PEGylated Fab fragment 58 investigational therapies 58 postoperative ileus 58 AGILECT R 58 TNFα 58 selective agonist 58 Cotara 58 ONTAK 58 RSD# oral 58 immunomodulating 58 Lu AA# 58 NNRTIs 58 Exelixis XL# 58 SERCA2a 58 multikinase inhibitor 58 NXL# 58 bifeprunox 58 anticancer activity 58 RAPAFLO 58 FTIs 58 Tamibarotene 58 partial agonists 58 AZX# 58 SCH # 58 omega interferon 58 xenograft models 58 Degarelix 58 albiglutide 58 PLK1 SNALP 58 HCV SPRINT 58 6R BH4 58 MAXY VII 58 recurrent GBM 58 Phase 1a clinical 58 ATryn ® 58 K ras 58 trastuzumab Herceptin R 58 Belimumab 58 tumorigenicity 58 bortezomib 58 biodistribution 58 PSN# [001] 58 nucleoside analogues 58 TYZEKA 58 AMN# [001] 58 davunetide 58 Squalamine 58 vitro studies 58 antiviral potency 58 kinase inhibition 58 EndoTAG TM 58 arimoclomol 58 PHX# 58 danoprevir 58 dose limiting toxicities 58 STRIDE PD 58 anti EGFR antibody 58 placebo controlled Phase 58 OMP #M# 58 vWF 58 flavopiridol 58 sJIA 58 Eg5 58 CD# CEA 58 immunoregulatory 58 alpha#beta# integrin 58 iniparib 58 Elitek 58 febuxostat 58 BZL# 58 sipuleucel T 58 R# #mg BID 58 tigecycline 58 potent inhibitor 58 Tolvaptan 58 MYDICAR 58 NF kB pathway 58 perifosine 58 OvaRex R 58 histone deacetylase HDAC inhibitor 58 oral taxane 58 DU #b 58 incretin 58 glucose lowering 58 ostarine 58 immune modulating 58 subcutaneously administered 58 #I TM# 58 SPRYCEL ® 58 favorable pharmacokinetic 58 MERLIN TIMI 58 Personalized Immunotherapy 58 PDGF receptor 58 torsemide ER 58 deferiprone 58 COX2 58 Fibrillex 58 TYGACIL